Stergios Kechagias

Professor

Linköping University
Country flagSweden

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Stergios Kechagias is a faculty member at Linköpings universitet in Sweden. His research focuses on liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and primary sclerosing cholangitis. Recent contributions to the field include studies on dietary habits and vitamin intake in liver disease patients, as well as the implications of genetic variants and non-invasive diagnostic methods for liver fibrosis. Professor Kechagias's work aims to enhance understanding of liver health and develop effective screening and management strategies.

Articles (16)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Aims To investigate the diagnostic accuracy of fecal calprotectin (FC) for inflammatory bowel disease (IBD) and organic gastrointestinal disease (OGID) in primary care. To examine the association with demographic factors, symptoms and concomitant medical therapy. Methods A retrospective analysis of data on all semiquantitative FC tests from individuals ≥18 years conducted in primary care in Östergötland County in 2010. A 5‐year follow‐up with inclusion of new gastrointestinal diagnoses. Results A total of 1293 eligible patients were included. IBD was found in 8.8% and other OGID in 30.8% of patients with positive FC. Positive FC was associated with diarrhea, age >60 years, duration <3 months, use of nonsteroidal anti‐inflammatory drug (NSAID), and proton pump inhibitor (PPI). Predictors of IBD were positive FC, diarrhea, rectal bleeding, and male sex; predictors of OGID positive FC, age >35 years, abnormal clinical findings, and duration <3 months. FC yielded the highest sensitivity and negative predictive value compared with demographic factors, symptoms, and duration. Use of NSAID and PPI showed a marginal increase in the sensitivity, positive predictive value, and decrease in the specificity of FC. Within 5 years, 4.0% had a new gastrointestinal diagnosis among patients with positive FC (0.6% IBD). Conclusions FC reliably rules out IBD and contradicts the presence of other OGID in primary care patients. Positive FC test together with other predictors, such as diarrhea, rectal bleeding, short duration, or age >35 years, should encourage a prioritized investigation. Use of NSAID, PPI, and ASA may affect the diagnostic accuracy of FC for IBD and OGID.

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (12)

Per Stal

Karolinska Institutet

SWEDEN
View details

Mattias Ekstedt

Linköping University

SWEDEN
View details

Henrik Hjortswang

-

SWEDEN
View details

Örjan Dahlström

Linköpings universitet Tekniska högskolan

SWEDEN
View details

Anna Oksanen

Karolinska Institutet

SWEDEN
View details

Martin Henriksson

Linköping University

SWEDEN
View details

Johan Rönnelid

Uppsala University

SWEDEN
View details

Fredrik Iredahl

Linköping University

SWEDEN
View details

Magnus Holmer

Karolinska University Hospital

SWEDEN
View details

Stefano Romeo

-

SWEDEN
View details

Catarina Lindqvist

Karolinska University Hospital

SWEDEN
View details

Karin Rådholm

Linköping University

SWEDEN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.